Moleculin Nears Critical Data Readout in AML Trial After Hitting Enrollment Milestone — Moleculin Biotech, Inc.

Event summary

Moleculin Biotech has enrolled 45 subjects in its MIRACLE trial for relapsed/refractory AML, triggering an interim data unblinding expected mid-2026.
Early blinded results showed a 40% remission rate in a difficult-to-treat patient population, including those who failed prior venetoclax therapies.
The trial's adaptive design aims for a streamlined global registration pathway, aligning with FDA Project Optimus principles.
Enrollment is accelerating toward 90 subjects, with Part A of the MIRACLE trial expected to conclude in Q3 2026.

The big picture

Moleculin's MIRACLE trial represents a pivotal moment in the development of next-generation anthracyclines for AML, addressing critical unmet needs in a difficult-to-treat patient population. The trial's adaptive design and alignment with FDA Project Optimus principles could streamline the path to approval, potentially positioning Annamycin as a game-changer in oncology. The upcoming data readout will be a key indicator of the drug's potential to overcome the limitations of current therapies, including cardiotoxicity and resistance mechanisms.

What we're watching

Regulatory Pathway: Whether the interim data will support an accelerated approval pathway based on the Complete Remission primary endpoint.
Execution Risk: The pace at which Moleculin can secure additional financing to support ongoing and future clinical trials.
Pipeline Momentum: How the MIRACLE trial's progress will influence the development of Annamycin in other indications, including soft tissue sarcoma and brain tumors.